The following table presents a summary of quarterly results of operations for fiscal 2013 and 2012:


	2013
	First Quarter		Second Quarter			Third Quarter			Fourth Quarter
Total revenue	$	631,362	$	612,663		$	626,136		$	622,118
Gross profit		281,673		279,326			309,758			290,631
Net income (loss) (1)		3,118		(51,104	)		(10,950	)		(1,113,902	)
Diluted net income (loss) per common share	$	0.01	$	(0.19	)	$	(0.04	)	$	(4.11	)


	2012
	First Quarter		Second Quarter			Third Quarter		Fourth Quarter(3)
Total revenue	$	472,711	$	471,165		$	470,228	$	588,548
Gross profit		249,370		226,110			244,640		274,317
Net income (loss) (2)		20,812		(40,273	)		23,594		(77,767	)
Diluted net income (loss) per common share	$	0.08	$	(0.15	)	$	0.09	$	(0.29	)

(1)

Net income in the first quarter of fiscal 2013 includes a gain on the sale of intellectual property of $53.9 million. Net loss in the second quarter of fiscal 2013 includes restructuring charges of $12.5 million and a debt extingushment loss of $3.2 million. Net loss in the third quarter of fiscal 2013 includes restructuring charges of $6.7 million. Net loss in the fourth quarter of fiscal 2013 includes a goodwill impairment charge of $1.1 billion, restructuring charges of $9.7 million and a debt extinguishment loss of $6.0 million.

(2)

Net loss in the second quarter of fiscal 2012 includes a charge for the discontinuance of the Adiana product line of $18.3 million and the loss on debt extinguishment of $42.3 million. See Note 5 for further discussion. Net loss in the fourth quarter of fiscal 2012 includes additional amortization expense from the Gen-Probe acquisition of $29.7 million, direct acquisition transaction costs of $30.7 million, and restructuring charges of $16.7 million, a goodwill impairment charge of $5.8 million and an in-process research and development charge of $4.5 million.

(3)	The fourth quarter was a 14-week quarter compared to all other quarters which were 13-week quarters.